Expression von Interleukin-4, Interleukin-4 Rezeptor, Interleukin-13 und Interleukin-13 Rezeptor in gastrointestinalen Tumoren und deren Rolle als prognostischer Faktor - eine retrospektive Untersuchung am Tumorgewebe von 454 Patienten
Auch gedruckt in der BibliothekW: W-H 13.273
Ressourcen- / MedientypDissertation, Text
Datum der Freischaltung2013-06-06
Background/aims: Interleukin-4 (IL-4) and Interleukin-13 (IL-13) are anti-inflammatory and immunomodulatory cytokines with close structural and biological homology. The aim of this study was to characterize their expression in primary colorectal and gastric cancer specimens, to evaluate possible functions for these diseases and to evaluate their prognostic value. Methods: Expression of IL-4, IL-13, IL-4R, and IL-13R protein was characterized by immunohistochemistry in 359 patients with colorectal and in 94 patients with gastric cancer, evaluated for their prognostic relevance. Results colorectal cancer: All four proteins were expressed in colorectal cancer specimens. Patients with high expression of IL-4, IL-4R and IL-13R had a lower frequency of lymph node metastases (p = 0,0034; p = 0,0001 and p = 0,0001). Expression of IL-13 did not influence the frequency of lymph node metastases. However, high IL-13-immunoreactivity was associated with a better overall survival (p = 0.041). Expression of IL-4, IL-4R, or IL-13R did not influence survival. Results gastric cancer: All four proteins were also expressed in gastric cancer specimens. High IL-4R-immunoreactivity was associated with a better disease free survival (p = 0,0355). However, expression of the other above mentioned cytokines did not influence overall survival or the frequency of lymph node metastases in gastric cancer specimens. Conclusions: Expression of IL-4, IL-4R, and IL-13R are involved in the process of local metastases in colorectal cancer, while IL-13 expression has an impact on survival. In gastric cancer expression of IL-4R had an impact on disease free survival. These interleukins and their receptors may become attractive targets for the treatment of colorectal and gastric cancer.